Tecentriq meets PFS endpoint in first-line TNBC

Genentech Inc. said Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival in the Phase III IMpassion130 trial as first-line treatment of triple-negative breast

Read the full 254 word article

User Sign In